Angiotensin receptor-neprilysin inhibitor treatment in people with chronic obstructive pulmonary disease and heart failure.

ABSTRACT:

Background

While renin-angiotensin system inhibitors (RASi) have shown benefits for people with both heart failure (HF) and chronic obstructive pulmonary disease (COPD), limited data exists on the use of angiotensin receptor-neprilysin inhibitors (ARNIs) in this population. This study compares the effectiveness of RASi and ARNIs in people with coexisting COPD and HF.

Methods

We identified individuals who started treatment with either ARNI or RASi since August 1, 2015. We assessed outcomes such as COPD exacerbations, acute respiratory failure, and lower respiratory tract infections (LRTIs) over 30 days to 3 years. Kaplan-Meier survival analysis and Cox regression models were applied to estimate survival probabilities and hazard ratios (HR).

Results

Among 9,071 ARNI use

SUBMITTER: Hsu WH 

PROVIDER: S-EPMC12532997 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature